

Jeffrey M. Zirger,

*Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.*

[FR Doc. 2019-03099 Filed 2-21-19; 8:45 am]

BILLING CODE 4163-18-P

**DEPARTMENT OF HEALTH AND
HUMAN SERVICES**

**Centers for Disease Control and
Prevention**

**Clinical Laboratory Improvement
Advisory Committee (CLIAC)**

AGENCY: Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).

ACTION: Notice of meeting.

SUMMARY: In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
for the Clinical Laboratory Improvement
Advisory Committee (CLIAC). This
meeting is open to the public, limited
only by the space available. The meeting
room accommodates approximately 100
people. The public is also welcome to
view the meeting by webcast. Check the
CLIAC website on the day of the
meeting for the webcast link
www.cdc.gov/cliac.

DATES: The meeting will be held on
April 10, 2019, 8:30 a.m. to 6:00 p.m.,
EDT and April 11, 2019, 8:30 a.m. to
1:00 p.m., EDT.

ADDRESSES: The Centers for Medicare &
Medicaid Services, 7500 Security
Boulevard, Baltimore, Maryland 21244
and via webcast at www.cdc.gov/cliac.

FOR FURTHER INFORMATION CONTACT:
Nancy Anderson, MMSc, MT(ASCP),
Senior Advisor for Clinical Laboratories,
Division of Laboratory Systems, Center
for Surveillance, Epidemiology and
Laboratory Services, Office of Public
Health Scientific Services, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, Mailstop V24-3,
Atlanta, Georgia 30329-4018, telephone
(404) 498-2741; NAnderson@cdc.gov.

SUPPLEMENTARY INFORMATION:

Purpose: This Committee is charged
with providing scientific and technical
advice and guidance to the Secretary of
Health and Human Services (HHS); the
Assistant Secretary for Health; the
Director, Centers for Disease Control
and Prevention; the Commissioner,
Food and Drug Administration (FDA);
and the Administrator, Centers for
Medicare and Medicaid Services (CMS).
The advice and guidance pertain to
general issues related to improvement in
clinical laboratory quality and
laboratory medicine practice and

specific questions related to possible
revision of the Clinical Laboratory
Improvement Amendment (CLIA)
standards. Examples include providing
guidance on studies designed to
improve safety, effectiveness, efficiency,
timeliness, equity, and patient-
centeredness of laboratory services;
revisions to the standards under which
clinical laboratories are regulated; the
impact of proposed revisions to the
standards on medical and laboratory
practice; and the modification of the
standards and provision of non-
regulatory guidelines to accommodate
technological advances, such as new
test methods, the electronic
transmission of laboratory information,
and mechanisms to improve the
integration of public health and clinical
laboratory practices.

All people attending the CLIAC
meeting in-person are required to
register for the meeting online at least
five business days in advance for U.S.
citizens and at least 15 business days in
advance for international registrants.
Register at www.cdc.gov/cliac. Register
by scrolling down and clicking the
“Register for this Meeting” button and
completing all forms according to the
instructions given. Please complete all
the required fields before submitting
your registration and submit no later
than April 2, 2019 for U.S. registrants
and March 19, 2019 for international
registrants.

It is the policy of CLIAC to accept
written public comments and provide a
brief period for oral public comments on
agenda items. Public comment periods
for each agenda item are scheduled
immediately prior to the Committee
discussion period for that item. In
general, each individual or group
requesting to make oral comments will
be limited to a total time of five minutes
(unless otherwise indicated). To assure
adequate time is scheduled for public
comments, speakers should notify the
contact person below at least five
business days prior to the meeting date.
For individuals or groups unable to
attend the meeting, CLIAC accepts
written comments until the date of the
meeting (unless otherwise stated).
However, it is requested that comments
be submitted at least five business days
prior to the meeting date so that the
comments may be made available to the
Committee for their consideration and
public distribution. Written comments,
one hard copy with original signature,
should be provided to the contact
person at the mailing or email address
below, and will be included in the
meeting’s Summary Report.

The CLIAC meeting materials will be
made available to the Committee and

the public in electronic format (PDF) on
the internet instead of by printed copy.
Check the CLIAC website on the day of
the meeting for materials: [www.cdc.gov/
cliac](http://www.cdc.gov/cliac).

Matters to be Considered: The agenda
will include agency updates from CDC,
CMS, and FDA. Presentations and
discussions will focus on an update
from the CDC’s Office of Infectious
Diseases Board of Scientific Counselors
meeting and reports from three CLIAC
workgroups: the CLIA Personnel
Regulations Workgroup, the
Nontraditional Testing Workflow Model
Workgroup, and the Next Generation
Sequencing Workgroup. Agenda items
are subject to change as priorities
dictate.

The Chief Operating Officer, Centers
for Disease Control and Prevention, has
been delegated the authority to sign
Federal Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.

Sherri Berger,

*Chief Operating Officer, Centers for Disease
Control and Prevention.*

[FR Doc. 2019-03009 Filed 2-21-19; 8:45 am]

BILLING CODE 4163-19-P

**DEPARTMENT OF HEALTH AND
HUMAN SERVICES**

**Centers for Disease Control and
Prevention**

**Board of Scientific Counselors,
National Center for Injury Prevention
and Control, NCIPC; Correction**

Notice is hereby given of a change in
the meeting of the Board of Scientific
Counselors, National Center for Injury
Prevention and Control; March 14, 2019,
02:00 p.m. to 05:00 p.m. EDT which was
published in the **Federal Register** on
January 30, 2019 Volume 84, Number
20, page 473.

The meeting is being changed to a
partially open and partially closed
meeting. This meeting will be open to
the public from 02:00 p.m.–02:40 p.m.
to update the public on the Opioid
Prescribing Estimate project. The dial in
number for the open portion of the
meeting is as follows: 1-866-880-0098;
Conference ID: 31769267. The meeting
will be closed to the public from 02:45
p.m.–05:00 p.m.

FOR FURTHER INFORMATION CONTACT:

Gwendolyn H. Cattledge, Ph.D.,
M.S.E.H., Deputy Associate Director for
Science, National Center for Injury
Prevention and Control, CDC, 4770